Directly Acting Anti-Viral Drugs And It's Metabolic Side Effects In Patients With Chronic Hcv

Abstract

HCV infection is a major cause of liver cirrhosis, (HCC) and end-stage liver disease. The development of an interferon-free, all-oral treatment regimen represents an important advance. We evaluated daclatasvir (an HCV NS5A replication complex inhibitor) plus sofosbuvir (a nucleotide analogue HCV NS5B polymerase inhibitor) with or without Ribavirin in chronic HCV patients. Results